SPH5030

· Shanghai Pharmaceuticals Holding Co., Ltd

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SPH5030, covering 2025-08-17 to 2025-08-17. Get the full timeline:

Most recent: Clinical Trial Update: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors [EARLY_Phase 1]